title: Advantages and drawbacks of long-term macrolide use in the treatment of non-cystic fibrosis bronchiectasis.
abstract: Non-cystic fibrosis (non-CF) bronchiectasis is a respiratory disease characterized by persistent airway inflammation and dilation of bronchial wall driven by various causes. Patients with bronchiectasis suffer from excessive sputum production, recurrent exacerbations, and progressive airway destruction. Major therapy for bronchiectasis is focused on breaking the "vicious cycle" of mucus stasis, infection, inflammation, and airway destruction. Growing evidences have been shown that macrolides possess immunoregulatory and anti-inflammatory functions beyond their antimicrobial effects. Macrolide antibiotics have been effectively used in the treatment of diffuse panbronchiolitis, CF and bronchiolitis obliterans syndrome. Currently a number of clinical trials were performed to assess macrolide treatment in the management of non-CF bronchiectasis. The purpose of this paper is to review the efficacy and potential risks of these recent studies on the use of macrolides in non-CF bronchiectasis.
authors.affiliation: Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
authors.forename: Li-Chao
authors.initials: LC
authors.lastname: Fan
authors.affiliation: Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
authors.forename: Jin-Fu
authors.initials: JF
authors.lastname: Xu
keywords: Macrolides; advantages; bronchiectasis; drawbacks
references.citation: Eur J Pharmacol. 2011 Aug 31;665(1-3):29-39
references.pmid: 21554873
references.citation: J Dermatol Sci. 2008 Mar;49(3):195-205
references.pmid: 18036782
references.citation: Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
references.pmid: 17277290
references.citation: Thorax. 1997 Oct;52(10):915-8
references.pmid: 9404381
references.citation: Eur Respir J. 1997 May;10(5):994-9
references.pmid: 9163637
references.citation: JAMA. 2013 Mar 27;309(12):1251-9
references.pmid: 23532241
references.citation: Curr Opin Pulm Med. 2014 Mar;20(2):153-8
references.pmid: 24378875
references.citation: PLoS One. 2013 Aug 01;8(8):e71109
references.pmid: 23936489
references.citation: Eur Respir J. 1999 Feb;13(2):361-4
references.pmid: 10065682
references.citation: Respirology. 2014 Apr;19(3):321-9
references.pmid: 24417869
references.citation: Thorax. 2006 Oct;61(10):895-902
references.pmid: 16809416
references.citation: Lancet Respir Med. 2013 Oct;1(8):610-620
references.pmid: 24461664
references.citation: Pharmacology. 2014;93(1-2):92-9
references.pmid: 24556631
references.citation: JAMA. 2013 Mar 27;309(12):1260-7
references.pmid: 23532242
references.citation: Inflammopharmacology. 2013 Aug;21(4):321-38
references.pmid: 23446952
references.citation: Respirology. 2013 Oct;18(7):1056-62
references.pmid: 23714268
references.citation: Treat Respir Med. 2005;4(2):117-22
references.pmid: 15813663
references.citation: J Heart Lung Transplant. 2010 Dec;29(12):1358-68
references.pmid: 20619683
references.citation: Thorax. 2010 Jul;65 Suppl 1:i1-58
references.pmid: 20627931
references.citation: Chest. 2012 Aug;142(2):432-439
references.pmid: 22302301
references.citation: Eur J Respir Dis Suppl. 1986;147:6-15
references.pmid: 3533593
references.citation: Am J Respir Crit Care Med. 2006 Oct 15;174(8):928-34
references.pmid: 16858014
references.citation: Lancet Respir Med. 2013 May;1(3):262-74
references.pmid: 24429132
references.citation: Lancet. 2012 Aug 18;380(9842):660-7
references.pmid: 22901887
references.citation: Clin Microbiol Rev. 2010 Jul;23(3):590-615
references.pmid: 20610825
references.citation: Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1829-32
references.pmid: 9620913